Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
765.370.03%
QQQ
709.600.05%
BTC/USD
77084.240.2999%
DIA
530.790.03%
GLD
402.030.19%
TLT
81.95-

Moleculin Biotech Inc

MBRXNASDAQ
Trade with Public
Trade with Public
$0.6940
0.0446.77%
At close: Sep 2, 5:00 PM EST
$0.6905
-0.0035-0.5%
After Hours: 7:20 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareStock Report

Moleculin Biotech Analyst Price Targets

Wall Street analyst price targets and consensus rating for Moleculin Biotech (MBRX).

Price Target Range — 10 Quarters

Analyst Consensus — 3 Analysts

3Buy
Consensus RatingBuy# Analysts3Avg. Consensus PT$12Upside to Avg. PT+1608.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 28, 2026HC Wainwright & Co.Sara NikPT CutBuy$22→$3
Mar 24, 2026HC Wainwright & Co.Sara NikMaintainedBuy$22
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on Moleculin Biotech, Lowers Price Target to $3

HC Wainwright & Co. analyst Sara Nik maintains Moleculin Biotech (NASDAQ:MBRX) with a Buy and lowers the price target from $22 to $3.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Moleculin Biotech, Maintains $22 Price Target

HC Wainwright & Co. analyst Sara Nik reiterates Moleculin Biotech (NASDAQ:MBRX) with a Buy and maintains $22 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Moleculin Biotech, Raises Price Target to $22

HC Wainwright & Co. analyst Sara Nik maintains Moleculin Biotech (NASDAQ:MBRX) with a Buy and raises the price target from $4 to $22.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Moleculin Biotech, Maintains $4 Price Target

HC Wainwright & Co. analyst Sara Nik reiterates Moleculin Biotech (NASDAQ:MBRX) with a Buy and maintains $4 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Moleculin Biotech, Maintains $4 Price Target

HC Wainwright & Co. analyst Sara Nik reiterates Moleculin Biotech (NASDAQ:MBRX) with a Buy and maintains $4 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Moleculin Biotech, Maintains $4 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Moleculin Biotech (NASDAQ:MBRX) with a Buy and maintains $4 price target.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved